Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 35
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Genotyping Hepatitis B virus by Next-Generation Sequencing, Detection of Mixed Infections and Analysis of Sequence Conservation

  • Dopico, Eva|||0000-0002-5306-3035
  • Vila, Marta|||0000-0001-9303-5189
  • Tabernero, David|||0000-0002-1146-4084
  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Rando-Segura, Ariadna|||0000-0003-4555-7286
  • Pacín Ruiz, Beatriz|||0000-0001-8718-6589
  • Guerrero, Laura|||0000-0003-1978-9067
  • Ubillos, Itziar|||0000-0002-0993-0058
  • Martínez, Miguel J.|||0000-0002-0682-1075
  • Costa, Josep|||0000-0001-7978-0748
  • Quer, Josep|||0000-0003-0014-084X
  • Pérez Garreta, Javier
  • González Sánchez, Alejandra|||0000-0002-1809-3415
  • Antón Pagarolas, Andrés, 1976-|||0000-0002-1476-0815
  • Pumarola Suñé, Tomàs|||0000-0002-5171-7461
  • Riveiro Barciela, Mar|||0000-0001-9309-2052
  • Ferrer Costa, Roser|||0000-0002-8925-3172
  • Buti, Maria|||0000-0002-0732-3078
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
  • Cortese, Maria Francesca|||0000-0002-4318-532X
Our aim was to develop an accurate, highly sensitive method for HBV genotype determination and detection of genotype mixtures. We examined the preS and 5' end of the HBV X gene (5X) regions of the HBV genome using next-generation sequencing (NGS). The 1852 haplotypes obtained were subjected to genotyping via the Distance-Based discrimination method (DB Rule) using two sets of 95 reference sequences of genotypes A-H. In clinical samples from 125 patients, the main genotypes were A, D, F and H in Caucasian, B and C in Asian and A and E in Sub-Saharan patients. Genotype mixtures were identified in 28 (22.40%) cases, and potential intergenotypic recombination was observed in 29 (23.20%) cases. Furthermore, we evaluated sequence conservation among haplotypes classified into genotypes A, C, D, and E by computing the information content. The preS haplotypes exhibited limited shared conserved regions, whereas the 5X haplotypes revealed two groups of conserved regions across the genotypes assessed. In conclusion, we developed an NGS-based HBV genotyping method utilizing the DB Rule for genotype classification. We identified two regions conserved across different genotypes at 5X, offering promising targets for RNA interference-based antiviral therapies.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Association of Liver Damage and Quasispecies Maturity in Chronic HCV Patients, The Fate of a Quasispecies

  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Ibañez Lligoña, Marta|||0000-0003-3428-2168
  • Colomer Castell, Sergi|||0000-0002-0307-7455
  • Campos, Carolina|||0000-0002-0132-7027
  • Garcia-Cehic, D.|||0000-0002-0009-038X
  • Quer, Josep|||0000-0003-0014-084X
Viral diversity and disease progression in chronic infections, and particularly how quasispecies structure affects antiviral treatment, remain key unresolved issues. Previous studies show that advanced liver fibrosis in long-term viral infections is linked to higher rates of antiviral treatment failures. Additionally, treatment failure is associated with high quasispecies fitness, which indicates greater viral diversity and adaptability. As a result, resistant variants may emerge, reducing retreatment effectiveness and increasing the chances of viral relapse. Additionally, using a mutagenic agent in monotherapy can accelerate virus evolution towards a flat-like quasispecies structure. This study examines 19 chronic HCV patients who failed direct-acting antiviral (DAA) treatments, using NGS to analyze quasispecies structure in relation to fibrosis as a marker of infection duration. Results show that HCV evolves towards a flat-like quasispecies structure over time, leading also to advanced liver damage (fibrosis F3 and F4/cirrhosis). Based on our findings and previous research, we propose that the flat-like fitness quasispecies structure is the final stage of any quasispecies in chronic infections unless eradicated. The longer the infection persists, the lower the chances of achieving a cure. Interestingly, this finding may also be applicable to other chronic infection and drug resistance in cancer.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Clinical value of plasma pTau181 to predict Alzheimer's disease pathology in a large real-world cohort of a memory clinic

  • Cano, Amanda|||0000-0001-9567-4283
  • Capdevila, María
  • Puerta, Raquel|||0000-0002-1191-5893
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Montrreal Navarro, Laura|||0000-0002-0010-645X
  • De Rojas, Itziar|||0000-0002-2148-381X
  • García-González, Pablo|||0000-0003-0125-5403
  • Olivé Roig, Clàudia|||0000-0002-9438-5639
  • García-Gutiérrez, Fernando
  • Sotolongo Grau, Oscar|||0000-0002-9679-0670
  • Orellana del Río, Adelina|||0000-0002-0204-1944
  • Aguilera, Nuria
  • Ramis, Maribel
  • Rosende-Roca, Maite
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
  • Tartari, Juan Pablo
  • Lafuente, Asunción
  • Vargas, Liliana|||0000-0001-5685-5903
  • Pérez-Cordón, Alba|||0000-0002-6028-0791
  • Muñoz, Nathalia
  • Sanabria, Ángela|||0000-0002-7501-9895
  • Alegret, Montserrat|||0000-0002-8164-9500
  • Morató, Xavier|||0000-0002-3012-2864
  • Tárraga, Lluís|||0000-0002-8423-946X
  • Fernández, Victoria
  • Marquié, Marta|||0000-0002-0660-0950
  • Valero, Sergi|||0000-0002-6599-948X
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Boada, Mercè|||0000-0003-2617-3009
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
The identification of patients with an elevated risk of developing Alzheimer's disease (AD) dementia and eligible for the disease-modifying treatments (DMTs) in the earliest stages is one of the greatest challenges in the clinical practice. Plasma biomarkers has the potential to predict these issues, but further research is still needed to translate them to clinical practice. Here we evaluated the clinical applicability of plasma pTau181 as a predictive marker of AD pathology in a large real-world cohort of a memory clinic. Methods: Three independent cohorts (modelling [n = 991, 59.7% female], testing [n = 642, 56.2% female] and validation [n = 441, 55.1% female]) of real-world patients with subjective cognitive decline (SCD), mild cognitive impairment (MCI), AD dementia, and other dementias were included. Paired cerebrospinal fluid (CSF) and plasma samples were used to measure AT(N) CSF biomarkers and plasma pTau181. CSF and plasma pTau181 showed correlation in all phenotypes except in SCD and other dementias. Age significantly influenced the biomarker's performance. The general Aβ(+) vs Aβ(-) ROC curve showed an AUC = 0.77 [0.74-0.80], whereas the specific ROC curve of MCI due to AD vs non-AD MCI showed an AUC = 0.89 [0.85-0.93]. A cut-off value of 1.30 pg/ml of plasma pTau181 exhibited a sensitivity of 93.57% [88.72-96.52], specificity of 72.38% [62.51-79.01], VPP of 77.85% [70.61-83.54], and 8.30% false negatives in the subjects with MCI of the testing cohort. The HR of cox regression showed that patients with MCI up to this cut-off value exhibited a HR = 1.84 [1.05-3.22] higher risk to convert to AD dementia than patients with MCI below the cut-off value. Plasma pTau181 has the potential to be used in the memory clinics as a screening biomarker of AD pathology in subjects with MCI, presenting a valuable prognostic utility in predicting the MCI conversion to AD dementia. In the context of a real-world population, a confirmatory test employing gold-standard procedures is still advisable. This study has been mainly funded by Ace Alzheimer Center Barcelona, Instituto de Salud Carlos III (ISCIII), Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED), Spanish Ministry of Science and Innovation, Fundación ADEY, Fundación Echevarne and Grífols S.A.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Deep Sequencing Reveals Dual Evolution of SARS-CoV-2, Insights Into Defective Genomes From Wuhan-Hu-1 Variants to Omicron Subvariants

  • Campos, Carolina|||0000-0002-0132-7027
  • Ibañez Lligoña, Marta|||0000-0003-3428-2168
  • Colomer Castell, Sergi|||0000-0002-0307-7455
  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Garcia-Cehic, D.|||0000-0002-0009-038X
  • Andrés, Cristina|||0000-0002-3200-0895
  • Piñana, Maria|||0000-0002-4766-2613
  • González Sánchez, Alejandra|||0000-0002-1809-3415
  • Rando-Segura, Ariadna|||0000-0003-4555-7286
  • Esperalba, Juliana|||0000-0003-1326-1341
  • Saubi, Narcis|||0000-0001-5493-1044
  • Cortese, Maria Francesca|||0000-0002-4318-532X
  • Tabernero, David|||0000-0002-1146-4084
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
  • Ferrer Costa, Roser|||0000-0002-8925-3172
  • Esteban Mur, Juan Ignacio|||0000-0001-5085-917X
  • Kakze-van der Honing, Renate W.
  • Kampfraath, Andries A.
  • Vergara-Alert, Júlia|||0000-0001-7484-444X
  • Segalés Coma, Joaquim|||0000-0002-1539-7261
  • van der Poel, Wim H. M.
  • Pumarola Suñé, Tomàs|||0000-0002-5171-7461
  • Antón Pagarolas, Andrés, 1976-|||0000-0002-1476-0815
  • Quer, Josep|||0000-0003-0014-084X
SARS-CoV-2 has evolved from early variants dominating the first (B.1.5, B.1.1) and second (B.1.177) pandemic waves, which exhibited a higher frequency of minority mutants with deletions leading to Defective Viral Genomes (DVGs) in the spike region near the S1/S2 cleavage site than the Alpha, Beta, and Delta variants. The emergence of Omicron has significantly altered the dominant variant profile, with Omicron subvariants now representing 100% of circulating viruses. To monitor the evolution and adaptation of Omicron in the human population, a deep-sequencing study was performed in RNA samples of BA.1, BA.1.1, BA.2, BA.5, BQ.1.1, XBB.1.5 and BA.2.86 Omicron subvariants. The findings reveal two occurrences of similar evolutionary patterns within SARS-CoV-2 characterized by a shift from a significant to a very low production of DVGs. This event suggests that DVGs might play a role in the virus's spread and adaptation for persistence in infected humans.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Comparison of Extracellular Vesicle Isolation Methods for miRNA Sequencing

  • Llorens-Revull, Meritxell|||0000-0002-8671-8907
  • Martínez-González, Brenda|||0000-0002-4482-5181
  • Quer, Josep|||0000-0003-0014-084X
  • Esteban Mur, Juan Ignacio|||0000-0001-5085-917X
  • Núñez-Moreno, Gonzalo|||0000-0001-5982-570X
  • Minguez, Pablo|||0000-0003-4099-9421
  • Burgui, Idoia
  • Ramos-Ruiz, Ricardo|||0000-0002-6331-9786
  • Soria Benito, María Eugenia|||0000-0002-4719-3351
  • Rico, Angie
  • Riveiro Barciela, Mar|||0000-0001-9309-2052
  • Sauleda, Silvia|||0000-0001-7343-9557
  • Piron, Maria|||0000-0001-6858-9374
  • Corrales Insa, Irene|||0000-0002-0647-0340
  • Borràs i Serres, Francesc Enric|||0000-0003-4038-1912
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
  • Rando-Segura, Ariadna|||0000-0003-4555-7286
  • Ramírez Serra, Clara|||0000-0001-8971-1711
  • Camós Anguila, Sílvia|||0000-0002-0478-8494
  • Domingo, Esteban
  • Bes, Marta|||0000-0001-6103-072X
  • Perales Viejo, Celia|||0000-0003-1618-1937
  • Costafreda Salvany, Maria Isabel|||0000-0002-3114-3034
MicroRNAs (miRNAs) encapsulated in extracellular vesicles (EVs) are potential diagnostic and prognostic biomarkers. However, discrepancies in miRNA patterns and their validation are still frequent due to differences in sample origin, EV isolation, and miRNA sequencing methods. The aim of the present study is to find a reliable EV isolation method for miRNA sequencing, adequate for clinical application. To this aim, two comparative studies were performed in parallel with the same human plasma sample: (i) isolation and characterization of EVs obtained using three procedures: size exclusion chromatography (SEC), iodixanol gradient (GRAD), and its combination (SEC+GRAD) and (ii) evaluation of the yield of miRNA sequences obtained using NextSeq 500 (Illumina) and three miRNA library preparation protocols: NEBNext, NEXTFlex, and SMARTer smRNA-seq. The conclusion of comparison (i) is that recovery of the largest amount of EVs and reproducibility were attained with SEC, but GRAD and SEC+GRAD yielded purer EV preparations. The conclusion of (ii) is that the NEBNext library showed the highest reproducibility in the number of miRNAs recovered and the highest diversity of miRNAs. These results render the combination of GRAD EV isolation and NEBNext library preparation for miRNA retrieval as adequate for clinical applications using plasma samples.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Solved the enigma of pediatric severe acute hepatitis of unknown origin?

  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
  • Rando-Segura, Ariadna|||0000-0003-4555-7286
  • Quer, Josep|||0000-0003-0014-084X
Hepatitis is an inflammation of the liver whose etiology is very heterogeneous. The most common cause of hepatitis is viral infections from hepatotropic viruses, including hepatitis A, B, C, D and E. However, other factors such as infections from other agents, metabolic disorders, or autoimmune reactions can also contribute to hepatitis, albeit to a lesser extent. On April 5, 2022, the United Kingdom Health Security Agency alerted the World Health Organization (WHO) on the increased incidence of severe acute hepatitis of unknown causes (not A-E) in previously healthy young children, with symptoms of liver failure that in some cases required liver transplantation. By July 2022, 1,296 cases were reported in 37 countries. Acute hepatitis of unknown causes is not an exceptional phenomenon: in fact, it represents more than 30% of cases of acute hepatitis in children, however in the present instance the large proportion of severe cases was surprising and alarming (6% of liver transplants and almost 3% mortality). Multiple hypotheses have been proposed to explain the etiology of such higher proportion of acute hepatitis, including their co-occurrence in the context of COVID-19 pandemic. This is a review of the history of a clinical threat that has put in check a world health care system highly sensitized by the current COVID-19 pandemics, and that it looks like has ended with the arguments that the severe acute pediatric hepatitis is caused by Adeno-associated virus 2 (AAV2) infection associated with a coinfection with a helper virus (human Adenovirus HAdV or human herpesvirus 6) in susceptible children carrying HLA-class II antigen HLA-DRB1*04:01.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Viral Quasispecies Inference from Single Observations-Mutagens as Accelerators of Quasispecies Evolution

  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Salicrú, Miquel|||0000-0001-9644-5626
  • Ibañez Lligoña, Marta|||0000-0003-3428-2168
  • Colomer Castell, Sergi|||0000-0002-0307-7455
  • Campos, Carolina|||0000-0002-0132-7027
  • González-Camuesco, Alvaro
  • Quer, Josep|||0000-0003-0014-084X
RNA virus populations exist as quasispecies-complex, dynamic clouds of closely related but genetically diverse variants generated by high mutation rates during replication. Assessing quasispecies structure and diversity is crucial for understanding viral evolution, adaptation, and response to antiviral treatments. However, comparing single quasispecies observations from individual biosamples, especially at different infection or treatment time points, presents statistical challenges. Traditional inferential tests are inapplicable due to the lack of replicate observations, and resampling-based approaches such as the bootstrap and jackknife are limited by biases and non-independence, particularly for diversity indices sensitive to rare haplotypes. In this study, we address these limitations by applying the delta method to derive analytical variances for a set of quasispecies structure indicators specifically designed to assess the quasispecies maturation state. We demonstrate the utility of this approach using high-depth next-generation sequencing data from hepatitis C virus (HCV) quasispecies evolving in vitro under various conditions, including free evolution and exposure to antiviral or mutagenic treatments. Our results reveal that with highly fit HCV quasispecies, sofosbuvir inhibits quasispecies genetic diversity, while mutagenic treatments accelerate maturation, compared to untreated controls. We emphasize the interpretation of results through absolute differences, log-fold changes, and standardized effect sizes, moving beyond mere statistical significance. This framework enables robust, quantitative comparisons of quasispecies diversity from single observations, providing valuable insights into viral adaptation and treatment response. The R code and session info with required libraries and versions is provided in the supplementary material.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

In-Host HEV Quasispecies Evolution Shows the Limits of Mutagenic Antiviral Treatments

  • Colomer Castell, Sergi|||0000-0002-0307-7455
  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Garcia-Cehic, D.|||0000-0002-0009-038X
  • Riveiro Barciela, Mar|||0000-0001-9309-2052
  • Buti, Maria|||0000-0002-0732-3078
  • Rando-Segura, Ariadna|||0000-0003-4555-7286
  • Vico-Romero, Judit|||0000-0003-2461-4317
  • Campos, Carolina|||0000-0002-0132-7027
  • Ibañez Lligoña, Marta|||0000-0003-3428-2168
  • Adombi, Caroline Melanie|||0000-0001-9739-9166
  • Cortese, Maria Francesca|||0000-0002-4318-532X
  • Tabernero, David|||0000-0002-1146-4084
  • Esteban Mur, Juan Ignacio|||0000-0001-5085-917X
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
  • Quer, Josep|||0000-0003-0014-084X
Here, we report the in-host hepatitis E virus (HEV) quasispecies evolution in a chronically infected patient who was treated with three different regimens of ribavirin (RBV) for nearly 6 years. Sequential plasma samples were collected at different time points and subjected to RNA extraction and deep sequencing using the MiSeq Illumina platforms. Specifically, we RT-PCR amplified a single amplicon from the core region located in the open-reading frame 2 (ORF2). At the nucleotide level (genotype), our analysis showed an increase in the number of rare haplotypes and a drastic reduction in the frequency of the master (most represented) sequence during the period when the virus was found to be insensitive to RBV treatment. Contrarily, at the amino acid level (phenotype), our study revealed conservation of the amino acids, which is represented by a high prevalence of the master sequence. Our findings suggest that using mutagenic antivirals concomitant with high viral loads can lead to the selection and proliferation of a rich set of synonymous haplotypes that express the same phenotype. This can also lead to the selection and proliferation of conservative substitutions that express fitness-enhanced phenotypes. These results have important clinical implications, as they suggest that using mutagenic agents as a monotherapy treatment regimen in the absence of sufficiently effective viral inhibitors can result in diversification and proliferation of a highly diverse quasispecies resistant to further treatment. Therefore, such approaches should be avoided whenever possible.
Dipòsit Digital de Documents de la UAB
Publication Artículo preliminar (WorkingPaper)

A peripheral proteomic signature of Alzheimer's disease is identified in the plasma extracellular vesicles of mild cognitive impairment patients from a memory clinic, the BIOPEXAL study

  • Capdevila-Bayo, Maria
  • Rossi, Rosanna|||0000-0002-3656-2908
  • De Rojas, Itziar|||0000-0002-2148-381X
  • Puerta, Raquel|||0000-0002-1191-5893
  • Guzman, Laura
  • Carrasco Exposito, Marina|||0000-0001-8301-8000
  • Muñoz-Morales, Álvaro
  • Olivé Roig, Clàudia|||0000-0002-9438-5639
  • Montrreal Navarro, Laura|||0000-0002-0010-645X
  • García-González, Pablo|||0000-0003-0125-5403
  • Bayón-Buján, Paula
  • Miguel-Romero, Andrea
  • Calm, Berta
  • Sotolongo Grau, Oscar|||0000-0002-9679-0670
  • Orellana del Río, Adelina|||0000-0002-0204-1944
  • Tatinya, Natalia
  • Martínez, Marta
  • Alegret, Montserrat|||0000-0002-8164-9500
  • Sanz Cartagena, Mª Pilar
  • Fernández, Mª Victoria
  • Marquié, Marta|||0000-0002-0660-0950
  • Valero, Sergi|||0000-0002-6599-948X
  • Montalban, Xavier|||0000-0002-0098-9918
  • Camins, Antoni|||0000-0002-1229-5956
  • Ramírez-Reveco, Alfredo|||0000-0003-4782-4261
  • Martí, Mercè|||0000-0002-1846-0043
  • Pividori, María Isabel|||0000-0002-5266-7873
  • Boada, Mercè|||0000-0003-2617-3009
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
  • Ettcheto, Miren|||0000-0002-4301-7297
  • Cano, Amanda|||0000-0001-9567-4283
Aims: Alzheimer's disease (AD) is commonly diagnosed when neuronal damage is already established and irreversible. Achieving an accurate differential diagnosis in the preclinical and mild cognitive impairment (MCI) stage is one of the greatest challenges nowadays. Nanotechnological analysis of plasma extracellular vesicles (pEVs) are gaining attention as a promising tool for the early detection of AD pathology. This study aims to evaluate the proteomic profile of pEVs from patients with MCI and AD dementia to explore their potential as AD screening tools. Methods: pEVs were isolated by ultracentrifugation from 144 patients with MCI A-T-, MCI A+T+, and AD dementia. Nanoparticle tracking analysis and cryo-TEM were used to characterize the pEVs. CSF, serum and pEVs proteomics were carried out by using the multiplex PEA technology of Olink® proteomics, Inflammation and Neurology Explore 384 panels (768 proteins). Results: Characterization results showed that isolated plasma fraction corresponded in shape, size and concentration to EVs. Many pEVs neurology proteins involved in AD pathology significantly correlated (r > ± 0.30, p < 0.05) with their CSF homonyms, but not with their serum's. pEVs' proteome correlated with common AD signatures (CSF Aβ42 and pTau181, plasma pTau181, MMSE, NBACE, and Qalb) showing similar patterns to those observed with CSF biomarkers. Several pEVs neurology proteins didn't exhibit differences between the MCI A+T+ and AD dementia groups, whilst they did with MCI A-T-. Proteins in pEVs showed strong correlations with several measures of brain atrophy in MRI. Several neurology pEV proteins predicted conversion from MCI to AD dementia. Moreover, some of these showed a significant diagnostic accuracy of AD pathology. Conclusion: Preliminary results suggest that EVs biomarker signature could reflect AD pathology in the prodromal stages of AD continuum. However, further experiments are still needed for a better understanding of EVs' role in AD development and pathology dissemination.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Fitness-Dependent, Mild Mutagenic Activity of Sofosbuvir for Hepatitis C Virus

  • Martínez-González, Brenda
  • Gallego, Isabel
  • Gregori, Josep
  • Soria, María Eugenia
  • Somovilla, Pilar
  • Ávila, Ana Isabel de
  • García-Crespo, Carlos
  • Durán-Pastor, Antoni
  • Briones, Carlos
  • Gómez, Jordi
  • Quer, Josep
  • Domingo, Esteban
  • Perales, Celia
The concept of a mild mutagen was coined to describe a minor mutagenic activity exhibited by some nucleoside analogues that potentiated their efficacy as antiretroviral agents. In the present study, we report the mild mutagen activity of sofosbuvir (SOF) for hepatitis C virus (HCV). Serial passages of HCV in human hepatoma cells, in the presence of SOF at a concentration well below its cytotoxic concentration 50 (CC) led to pre-extinction populations whose mutant spectra exhibited a significant increase of C!U transitions, relative to populations passaged in the absence of SOF. This was reflected in an increase in several diversity indices that were used to characterize viral quasispecies. The mild mutagenic activity of SOF was largely absent when it was tested with isogenic HCV populations that displayed high replicative fitness. Thus, SOF can act as a mild mutagen for HCV, depending on HCV fitness. Possible mechanisms by which the SOF mutagenic activity may contribute to its antiviral efficacy are discussed., The work at CBMSO was supported by grants SAF2014-52400-R from Ministerio de Economía y Competitividad (MINECO); SAF2017-87846-R and BFU2017-91384-EXP from Ministerio de Ciencia, Innovación y Universidades (MCIU); project 525/C/2021 from Fundació La Marató de TV3; PID2020-113888RB-I00 and 202220I116 from Ministerio de Ciencia e Innovación (MICINN); PI18/00210, PI19/00301, PI21/00139, and PI22/00258 from Instituto de Salud Carlos III (ISCIII); S2013/ABI-2906 (PLATESA from Comunidad de Madrid/FEDER); and S2018/BAA-4370 (PLATESA2 from Comunidad de Madrid/FEDER). This research work was also funded by the European Commission-NextGenerationEU (regulation EU 2020/ 2094) through the CSIC’s Global Health Platform (PTI Salud Global). C.P. is supported by the Miguel Servet program of the ISCIII (CP14/00121 and CPII19/00001), cofinanced by the European Regional Development Fund (ERDF). B.M.-G. is supported by the predoctoral contract PFIS FI19/00119 from ISCIII, cofinanced by Fondo Social Europeo (FSE), “El FSE invierte en tu futuro”. C.G.-C. is supported by the predoctoral contract PRE2018-083422 from MCIU. P.S. is supported by the postdoctoral contract Margarita Salas, CA1/RSUE/ 2021 from MCIU. A.D.-P. is supported by the contract 13-2022-008566 cofinanced by the Comunidad de Madrid, through the Programa Investigo, en el marco del Plan de Recuperación, Transformación y Resiliencia, financed by the European Union-Next Generation EU. CIBERehd (Centro de Investigación en Red de Enfermedades Hepáticas y Digestivas), which is funded by ISCIII. The work at CAB was supported by the MICINN grant no. PID2019-104903RB-I00. Institutional grants from the Fundación Ramón Areces and Banco Santander to the CBMSO are also acknowledged. The team at CBMSO belongs to the Global Virus Network (GVN)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Otros (Other)

Connecting genomic and proteomic signatures of amyloid burden in the brain

  • Puerta, Raquel
  • de Rojas, Itziar
  • García-González, Pablo
  • Olivé-Roig, Claudia
  • Sotolongo-Grau, Oscar
  • García-Sánchez, Ainhoa
  • García-Gutiérrez, Fernando
  • Montrreal, Laura
  • Tartari, Juan Pablo
  • Sanabria, Ángela
  • Pytel, Vanesa
  • Lage, Carmen
  • Quintela, Ines
  • Aguilera, Nuria
  • Rodríguez-Rodríguez, Eloy
  • Alarcón-Martín, Emilio
  • Orellana, Adelina
  • Pastor, Pau
  • Pérez-Tur, Jordi
  • Pinol-Ripoll, Gerard
  • López de Munain, Adolfo
  • García-Alberca, José María
  • Royo, José Luis
  • Bullido, María Jesús
  • Álvarez, Victoria
  • Real, Luis Miguel
  • Corbatón Anchuelo, Arturo
  • Gómez-Garre, Dulcenombre
  • Martínez Larrad, María Teresa
  • Franco-Macias, Emilio
  • Mir, Pablo
  • Medina, Miguel
  • Sánchez-Valle, Raquel
  • Icardo, Oriol
  • Dols-Sáez, María Eugenia
  • Carracedo, Ángel
  • Tárraga, Lluís
  • Alegret, Montse
  • Valero, Sergi
  • Marquie, Marta
  • Boada, Mercè
  • Juan, Pascual
  • Sánchez Cavazos, José Enrique
  • Cabrera, Alfredo
  • Cano, Amanda
  • Ruiz, Agustín
preprint 42 páginas, 6 figuras, 2 tablas, Background: Alzheimer's disease (AD) has a high heritable component characteristic of complex diseases, yet many of the genetic risk factors remain unknown. We combined genome-wide association studies (GWAS) on amyloid endophenotypes measured in cerebrospinal fluid (CSF) and positron emission tomography (PET) as surrogates of amyloid pathology, which may be helpful to understand the underlying biology of the disease. Methods: We performed a meta-analysis of GWAS of CSF Aβ42 and PET measures combining six independent cohorts (n=2,076). Due to the opposite effect direction of Aβ phenotypes in CSF and PET measures, only genetic signals in the opposite direction were considered for analysis (n=376,599). Polygenic risk scores (PRS) were calculated and evaluated for AD status and amyloid endophenotypes. We then searched the CSF proteome signature of brain amyloidosis using SOMAscan proteomic data (Ace cohort, n=1,008) and connected it with GWAS results of loci modulating amyloidosis. Finally, we compared our results with a large meta-analysis using publicly available datasets in CSF (n=13,409) and PET (n=13,116). This combined approach enabled the identification of overlapping genes and proteins associated with amyloid burden and the assessment of their biological significance using enrichment analyses. Results: After filtering the meta-GWAS, we observed genome-wide significance in the rs429358-APOE locus and nine suggestive hits were annotated. We replicated the APOE loci using the large CSF-PET meta-GWAS and identified multiple AD-associated genes as well as the novel GADL1 locus. Additionally, we found a significant association between the AD PRS and amyloid levels, whereas no significant association was found between any Aβ PRS with AD risk. CSF SOMAscan analysis identified 1,387 FDR-significant proteins associated with CSF Aβ42 levels. The overlap among GWAS loci and proteins associated with amyloid burden was very poor (n=35). The enrichment analysis of overlapping hits strongly suggested several signalling pathways connecting amyloidosis with the anchored component of the plasma membrane, synapse physiology and mental disorders that were replicated in the large CSF-PET meta-analysis. Conclusions: The strategy of combining CSF and PET amyloid endophenotypes GWAS with CSF proteome analyses might be effective for identifying signals associated with the AD pathological process and elucidate causative molecular mechanisms behind the amyloid mobilization in AD., The Genome Research @ Ace Alzheimer Center Barcelona project (GR@ACE) is supported by Grifols SA, Fundación bancaria 'La Caixa', Ace Alzheimer Center Barcelona and CIBERNED. Ace Alzheimer Center Barcelona is one of the participating centers of the Dementia Genetics Spanish Consortium (DEGESCO). The FACEHBI study is supported by funds from Ace Alzheimer Center Barcelona, Grifols, Life Molecular Imaging, Araclon Biotech, Alkahest, Laboratorio de análisis Echevarne and IrsiCaixa. Authors acknowledge the support of the Spanish Ministry of Science and Innovation, Proyectos de Generación de Conocimiento grants PID2021-122473OA-I00, PID2021-123462OB-I00 and PID2019-106625RB-I00. ISCIII, Acción Estratégica en Salud, integrated in the Spanish National R+D+I Plan and financed by ISCIII Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER 'Una manera de hacer Europa') grants PI13/02434, PI16/01861, PI17/01474, PI19/00335, PI19/01240, PI19/01301, PI22/01403, PI22/00258 and the ISCIII national grant PMP22/00022, funded by the European Union (NextGenerationEU). The support of CIBERNED (ISCIII) under the grants CB06/05/2004 and CB18/05/00010. The support from the ADAPTED and MOPEAD projects, European Union/EFPIA Innovative Medicines Initiative Joint (grant numbers 115975 and 115985, respectively); from PREADAPT project, Joint Program for Neurodegenerative Diseases (JPND) grant AC19/00097; from HARPONE project, Agency for Innovation and Entrepreneurship (VLAIO) grant PR067/21 and Janssen. DESCARTES project is funded by German Research Foundation (DFG). Additionally, IdR is supported by the Instituto de Salud Carlos III (ISCIII) under grant FI20/00215. PGG is supported by CIBERNED employment plan (CNV-304-PRF-866). ACF received support from the ISCIII under the grant Sara Borrell (CD22/00125). JEC received support from National Institute of Health award P30AG066546., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Associations of plasma SMOC1 and soluble IL6RA levels with the progression from mild cognitive impairment to dementia

  • Morató, Xavier
  • Puerta, Raquel
  • Cano, Amanda
  • Orellana, Adelina
  • de Rojas, Itziar
  • Capdevila, María
  • Montrreal, Laura
  • Rosende-Roca, Maitée
  • García-González, Pablo
  • Olivé, Claudia
  • García-Gutiérrez, Fernando
  • Blázquez, Josep
  • Miguel, Andrea
  • Núñez-Llaves, Raúl
  • Pytel, Vanesa
  • Alegret, Montserrat
  • Fernández, María Victoria
  • Marquié, Marta
  • Valero, Sergi
  • Cavazos, Jose Enrique
  • Mañes, Santos
  • Boada, Mercè
  • Cabrera-Socorro, Alfredo
  • Ruiz, Agustín
Despite the central role attributed to neuroinflammation in the etiology and pathobiology of Alzheimer's disease (AD), the direct link between levels of inflammatory mediators in blood and cerebrospinal fluid (CSF) compartments, as well as their potential implications for AD diagnosis and progression, remains inconclusive. Moreover, there is debate on whether inflammation has a protective or detrimental effect on disease onset and progression. Indeed, distinct immunological mechanisms may govern protective and damaging effects at early and late stages, respectively. This study aims to (i) identify inflammatory mediators demonstrating robust correlations between peripheral and central nervous system (CNS) compartments by means of plasma and CSF analysis, respectively, and (ii) assess their potential significance in the context of AD and disease progression from mild cognitive impairment (MCI) to dementia. To achieve this, we have examined the inflammatory profile of a well-defined subcohort comprising 485 individuals from the Ace Alzheimer Center Barcelona (ACE). Employing a hierarchical clustering approach, we thoroughly evaluated the intercompartmental correlations of 63 distinct inflammation mediators, quantified in paired CSF and plasma samples, using advanced SOMAscan technology. Of the array of mediators investigated, only six mediators (CRP, IL1RAP, ILRL1, IL6RA, PDGFRB, and YKL-40) exhibited robust correlations between the central and peripheral compartments (proximity scores <400). To strengthen the validity of our findings, these identified mediators were subsequently validated in a second subcohort of individuals from ACE (n = 873). The observed plasma correlations across the entire cohort consistently have a Spearman rho value above 0.51 (n = 1,360, p < 1.77E-93). Of the high CSF-plasma correlated proteins, only soluble IL6RA (sIL6RA) displayed a statistically significant association with the conversion from MCI to dementia. This association remained robust even after applying a stringent Bonferroni correction (Cox proportional hazard ratio [HR] = 1.936 per standard deviation; p = 0.0018). This association retained its significance when accounting for various factors, including CSF amyloid (Aβ42) and Thr181-phosphorylated tau (p-tau) levels, age, sex, baseline Mini-Mental State Examination (MMSE) score, and potential sampling biases identified through principal component analysis (PCA) modeling. Furthermore, our study confirmed the association of both plasma and CSF levels of SPARC-related modular calcium-binding protein 1 (SMOC1) with amyloid and tau accumulation, indicating their role as early surrogate biomarkers for AD pathology. Despite the lack of a statistically significant correlation between SMOC1 levels in CSF and plasma, both acted as independent biomarkers of disease progression (HR > 1.3, p < 0.002). In conclusion, our study unveils that sIL6RA and SMOC1 are associated with MCI progression. The absence of correlations among inflammatory mediators between the central and peripheral compartments appears to be a common pattern, with only a few intriguing exceptions., A. Ruiz received support from the HARPONE project, Agency for Innovation and Entrepreneurship (VLAIO) grant Nº PR067/21 and Jansen; from the PREADAPT project, Joint Program for Neurodegenerative Diseases (JPND) grant Nº AC19/00097; from the ADAPTED project, EU/EFPIA Innovative Medicines Initiative Joint Undertaking grant Nº 115975; from the DESCARTES project, German Research Foundation (DFG); and from Fundación Bancaria“La Caixa”, Fundación Echevarne and Grifols S.A. (GR@ACE project). Research funding support for the analyses was granted to the Ace Alzheimer Center Barcelona (X. Morató and M. Boada) by Novo Nordisk. S. Manes received support from the Spanish Ministry of Science and Innovation (MCIN/AEI/10.13039/501100011033) (grant PID2020-116303RB-I00). The authors acknowledge the support of the Spanish Ministry of Science and Innovation, Proyectos de Generación de Conocimiento grant PID2021-122473OA-I00. Support was also given by Acción Estratégica en Salud, integrated into the Spanish National R +D +I Plan and financed by ISCIII Subdirección General de Evaluaci´ on and Fondo Europeo de Desarrollo Regional (FEDER“Una manera de hacer Europa") grants PI17/01474, PI19/00335, PI22/01403, and PI22/00258 and ISCIII national grant PMP22/00022, funded by the European Union (NextGenerationEU). The support of CIBERNED (ISCIII) under grants CB06/05/ 2004 and CB18/05/00010 is also acknowledged. A. Cano received support from the Instituto de Salud Carlos III (ISCIII) under the grant Sara Borrell (CD22/00125) and from Fundación ADEY (under the program“Proyectos de Investigacioón en Salud 2023”). I. de Rojas was supported by ISCIII under grant FI20/00215. P. García-Gonz´ alez was supported by the CIBERNED employment plan (CNV-304-PRF-866). S. Valero received support from the TARTAGLIA project, the program of the Spanish Ministry of Science and Innovation R&D Missions in Artificial Intelligence, the Spain Digital 2025 Agenda, and the National Artificial Intelligence Strategy, financed by the European Union through Next Generation EU funds, under grant Nº MIA.2021.M02.0005., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Linking genomic and proteomic signatures to brain amyloid burden: insights from GR@ACE/DEGESCO

  • Puerta, Raquel
  • Pérez-Tur, Jordi
  • Bullido, María Jesús
  • Real, Luis Miguel
  • Mir, Pablo
  • Ruiz, Agustín
  • Alzheimer’s Disease Neuroimaging Initiative
27 páginas, 7 figuras, 3 tablas, Alzheimer's disease (AD) is a complex disease with a strong genetic component, yet many genetic risk factors remain unknown. We combined genome-wide association studies (GWAS) on amyloid endophenotypes measured in cerebrospinal fluid (CSF) and positron emission tomography (PET) as surrogates of amyloid pathology, which may provide insights into the underlying biology of the disease. We performed a meta-GWAS of CSF Aβ42 and PET measures combining six independent cohorts (n = 2,076). Given the opposite beta direction of Aβ phenotypes in CSF and PET measures, only genetic signals showing opposite directions were considered for analysis (n = 376,599). We explored the amyloidosis signature in the CSF proteome using SOMAscan proteomics (ACE cohort, n = 1,008), connected it with GWAS loci modulating amyloidosis and performed an enrichment analysis of overlapping hits. Finally, we compared our results with a large meta-analysis using publicly available datasets in CSF (n = 13,409) and PET (n = 13,116). After filtering the meta-GWAS, we observed genome-wide significance in the rs429358-APOE locus and annotated nine suggestive hits. We replicated the APOE loci using the large CSF-PET meta-GWAS, identifying multiple AD-associated genes including the novel GADL1 locus. Additionally, we found 1,387 FDR-significant SOMAscan proteins associated with CSF Aβ42 levels. The overlap among GWAS loci and proteins associated with amyloid burden was minimal (n = 35). The enrichment analysis revealed mechanisms connecting amyloidosis with the plasma membrane's anchored component, synapse physiology and mental disorders that were replicated in the large CSF-PET meta-analysis. Combining CSF and PET amyloid GWAS with CSF proteome analyses may effectively elucidate causative molecular mechanisms behind amyloid mobilization and AD physiopathology., The Genome Research @ Ace Alzheimer Center Barcelona project (GR@ACE) is supported by Grifols SA, Fundación bancaria ‘La Caixa’, Ace Alzheimer Center Barcelona and CIBERNED. Ace Alzheimer Center Barcelona is one of the participating centers of the Dementia Genetics Spanish Consortium (DEGESCO). The FACEHBI study is supported by funds from Ace Alzheimer Center Barcelona, Grifols, Life Molecular Imaging, Araclon Biotech, Alkahest, Laboratorio de análisis Echevarne and IrsiCaixa. Authors acknowledge the support of the Spanish Ministry of Science and Innovation, Proyectos de Generación de Conocimiento grants PID2021-122473OA-I00, PID2021-123462OB-I00 and PID2019-106625RB-I00. ISCIII, Acción Estratégica en Salud, integrated in the Spanish National R + D + I Plan and financed by ISCIII Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER “Una manera de hacer Europa") grants PI13/02434, PI16/01861, PI17/01474, PI19/00335, PI19/01240, PI19/01301, PI22/01403, PI22/00258 and the ISCIII national grant PMP22/00022, funded by the European Union (NextGenerationEU). The support of CIBERNED (ISCIII) under the grants CB06/05/2004 and CB18/05/00010. The support from the ADAPTED and MOPEAD projects, European Union/EFPIA Innovative Medicines Initiative Joint (grant numbers 115975 and 115985, respectively); from PREADAPT project, Joint Program for Neurodegenerative Diseases (JPND) grant Nº AC19/00097; from HARPONE project, Agency for Innovation and Entrepreneurship (VLAIO) grant Nº PR067/21 and Janssen. DESCARTES project is funded by German Research Foundation (DFG). Additionally, AR is also supported by STAR Award. University of Texas System. Tx, United States, The South Texas ADRC. National Institute of Aging. National Institutes of Heath. USA. (P30AG066546) and the Keith M. Orme and Pat Vigeon Orme Endowed Chair in Alzheimer’s and Neurodegenerative Diseases. IdR is supported by the Instituto de Salud Carlos III (ISCIII) under grant FI20/00215. PGG is supported by CIBERNED employment plan (CNV-304-PRF-866). ACF received support from the ISCIII under the grant Sara Borrell (CD22/00125). JEC received support from National Institute of Health award P30AG066546., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Virus Quasispecies Rarefaction: Subsampling with or without Replacement?

  • Gregori Font, Josep
  • Ibañez Lligoña, Marta
  • Colomer-Castell, Sergi
  • Campos, Carolina
  • QUER, JOSEP
Haplotypes; Quasispecies; Rarefaction, Haplotips; Quasiespècie; Rarefacció, Haplotipos; Cuasiespecie; Rarefacción, In quasispecies diversity studies, the comparison of two samples of varying sizes is a common necessity. However, the sensitivity of certain diversity indices to sample size variations poses a challenge. To address this issue, rarefaction emerges as a crucial tool, serving to normalize and create fairly comparable samples. This study emphasizes the imperative nature of sample size normalization in quasispecies diversity studies using next-generation sequencing (NGS) data. We present a thorough examination of resampling schemes using various simple hypothetical cases of quasispecies showing different quasispecies structures in the sense of haplotype genomic composition, offering a comprehensive understanding of their implications in general cases. Despite the big numbers implied in this sort of study, often involving coverages exceeding 100,000 reads per sample and amplicon, the rarefaction process for normalization should be performed with repeated resampling without replacement, especially when rare haplotypes constitute a significant fraction of interest. However, it is noteworthy that different diversity indices exhibit distinct sensitivities to sample size. Consequently, some diversity indicators may be compared directly without normalization, or instead may be resampled safely with replacement., This study was partially supported by Plan Estratègic de Recerca i Innovació en Salut (PERIS)—Direcció General de Recerca i Innovació en Salut (DGRIS), Catalan Health Ministry, Generalitat de Catalunya; Centro para el Desarrollo Tecnológico Industrial (CDTI) from the Spanish Ministry of Economy and Business, grant number IDI-20200297; and Project PI22/00258 funded by Instituto de Salud Carlos III (ISCIII) and cofounded by the European Union. S.C.-C has received support from the Spanish Ministry of Education, grant FPU21/04150. M.I.-L. received the support of a fellowship from the “la Caixa” Foundation (ID 100010434), whose code is LCF/BQ/DR23/12000020, C.C. received a predoctoral fellowship from VHIR.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

In-Host HEV Quasispecies Evolution Shows the Limits of Mutagenic Antiviral Treatments

  • Vico-Romero, Judit
  • Campos, Carolina
  • Cortese, Maria Francesca
  • Colomer-Castell, Sergi
  • Gregori Font, Josep
  • Garcia-Cehic, Damir
  • Riveiro-Barciela, Mar
  • Rando Segura, Ariadna
  • Ibañez Lligoña, Marta
  • ADOMBI, Caroline Mélanie
  • Tabernero, David
  • Esteban Mur, Juan Ignacio
  • RODRIGUEZ-FRIAS, FRANCISCO
  • QUER, JOSEP
  • Buti Ferret, Maria
Deep sequencing; Mutagens; Quasispecies, Seqüenciació profunda; Mutàgens; Quasiespècie, Secuenciación profunda; Mutágenos; Cuasiespecie, Here, we report the in-host hepatitis E virus (HEV) quasispecies evolution in a chronically infected patient who was treated with three different regimens of ribavirin (RBV) for nearly 6 years. Sequential plasma samples were collected at different time points and subjected to RNA extraction and deep sequencing using the MiSeq Illumina platforms. Specifically, we RT-PCR amplified a single amplicon from the core region located in the open-reading frame 2 (ORF2). At the nucleotide level (genotype), our analysis showed an increase in the number of rare haplotypes and a drastic reduction in the frequency of the master (most represented) sequence during the period when the virus was found to be insensitive to RBV treatment. Contrarily, at the amino acid level (phenotype), our study revealed conservation of the amino acids, which is represented by a high prevalence of the master sequence. Our findings suggest that using mutagenic antivirals concomitant with high viral loads can lead to the selection and proliferation of a rich set of synonymous haplotypes that express the same phenotype. This can also lead to the selection and proliferation of conservative substitutions that express fitness-enhanced phenotypes. These results have important clinical implications, as they suggest that using mutagenic agents as a monotherapy treatment regimen in the absence of sufficiently effective viral inhibitors can result in diversification and proliferation of a highly diverse quasispecies resistant to further treatment. Therefore, such approaches should be avoided whenever possible., This study was partially supported by Plan Estratègic de Recerca i Innovació en Salut (PERIS)—Direcció General de Recerca i Innovació en Salut (DGRIS), Catalan Health Ministry, Generalitat de Catalunya; Centro para el Desarrollo Tecnológico Industrial (CDTI) from the Spanish Ministry of Economy and Business, grant number IDI-20200297, Grant PID2021-126447OB-I00 funded by MCIN/AEI/10.13039/501100011033 and by ERDF A way of making Europe; Projects PI19/00301 and PI22/00258 funded by Instituto de Salud Carlos III (ISCIII) and cofounded by the European Union; and Gilead’s biomedical research project GLD21/00006. S.C.-C has received support from Spanish Ministry of Education, grant FPU21/04150. M.I.-L. received the support of a fellowship from the “la Caixa” Foundation (ID 100010434), whose code is “LCF/BQ/DR23/12000020”.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Genotyping Hepatitis B virus by Next-Generation Sequencing: Detection of Mixed Infections and Analysis of Sequence Conservation

  • Dopico, Eva
  • Vila Salvador, Marta
  • Pacin Ruiz, Beatriz
  • Pérez Garreta, Javier
  • Buti Ferret, Maria
  • Tabernero, David
  • Gregori Font, Josep
  • Rando Segura, Ariadna
  • QUER, JOSEP
  • González-Sánchez, Alejandra
  • Pumarola Suñe, Tomàs
  • Riveiro-Barciela, Mar
  • Ferrer Costa, Roser
  • RODRIGUEZ-FRIAS, FRANCISCO
  • Cortese, Maria Francesca
  • Antón Pagarolas, Andrés
RNA interference; Hepatitis B X gene; Next-generation sequencing, Interferència d'ARN; Gen de l'hepatitis BX; Seqüenciació de nova generació, Interferencia de ARN; Gen de la hepatitis BX; Secuenciación de nueva generación, Our aim was to develop an accurate, highly sensitive method for HBV genotype determination and detection of genotype mixtures. We examined the preS and 5' end of the HBV X gene (5X) regions of the HBV genome using next-generation sequencing (NGS). The 1852 haplotypes obtained were subjected to genotyping via the Distance-Based discrimination method (DB Rule) using two sets of 95 reference sequences of genotypes A-H. In clinical samples from 125 patients, the main genotypes were A, D, F and H in Caucasian, B and C in Asian and A and E in Sub-Saharan patients. Genotype mixtures were identified in 28 (22.40%) cases, and potential intergenotypic recombination was observed in 29 (23.20%) cases. Furthermore, we evaluated sequence conservation among haplotypes classified into genotypes A, C, D, and E by computing the information content. The preS haplotypes exhibited limited shared conserved regions, whereas the 5X haplotypes revealed two groups of conserved regions across the genotypes assessed. In conclusion, we developed an NGS-based HBV genotyping method utilizing the DB Rule for genotype classification. We identified two regions conserved across different genotypes at 5X, offering promising targets for RNA interference-based antiviral therapies., This research was funded by the grant PID2021-126447OB-I00 funded by MCIN/AEI/10.13039/501100011033 and by ERDF A way of making Europe; Centro para el Desarrollo Tecnológico Industrial (CDTI) from the Spanish Ministry of Economy and Business, grant number IDI-20200297; Projects PI19/00301 and PI22/00258 funded by Instituto de Salud Carlos III (ISCIII) and cofounded by the European Union.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

In-Host Flat-like Quasispecies: Characterization Methods and Clinical Implications

  • Gregori Font, Josep
  • Colomer-Castell, Sergi
  • Ibañez Lligoña, Marta
  • Garcia-Cehic, Damir
  • Campos, Carolina
  • Riveiro-Barciela, Mar
  • Piñana, María
  • González-Sánchez, Alejandra
  • RODRIGUEZ-FRIAS, FRANCISCO
  • Cortese, Maria Francesca
  • Tabernero, David
  • Rando Segura, Ariadna
  • Pumarola Suñe, Tomàs
  • Esteban Mur, Juan Ignacio
  • QUER, JOSEP
  • Buti Ferret, Maria
  • Antón Pagarolas, Andrés
  • Andrés Vergés, Cristina
Cuasiespecies; Mutágenos; Mutaciones, Quasispecies; Mutagens; Mutations, Quasiespècie; Mutàgens; Mutacions, The repeated failure to treat patients chronically infected with hepatitis E (HEV) and C (HCV) viruses, despite the absence of resistance-associated substitutions (RAS), particularly in response to prolonged treatments with the mutagenic agents of HEV, suggests that quasispecies structure may play a crucial role beyond single point mutations. Quasispecies structured in a flat-like manner (referred to as flat-like) are considered to possess high average fitness, occupy a significant fraction of the functional genetic space of the virus, and exhibit a high capacity to evade specific or mutagenic treatments. In this paper, we studied HEV and HCV samples using high-depth next-generation sequencing (NGS), with indices scoring the different properties describing flat-like quasispecies. The significance of these indices was demonstrated by comparing the values obtained from these samples with those from acute infections caused by respiratory viruses (betacoronaviruses, enterovirus, respiratory syncytial viruses, and metapneumovirus). Our results revealed that flat-like quasispecies in HEV and HCV chronic infections without RAS are characterized by numerous low-frequency haplotypes with no dominant one. Surprisingly, these low-frequency haplotypes (at the nucleotide level) exhibited a high level of synonymity, resulting in much lower diversity at the phenotypic level. Currently, clinical approaches for managing flat-like quasispecies are lacking. Here, we propose methods to identifying flat-like quasispecies, which represents an essential initial step towards exploring alternative treatment protocols for viruses resistant to conventional therapies., This study was partially supported by Centro para el Desarrollo Tecnológico Industrial (CDTI) from the Spanish Ministry of Economy and Business, grant number IDI-20200297; Grant PID2021-126447OB-I00 funded by MCIN/AEI/10.13039/501100011033 and by ERDF A way of making Europe; Fondo de Investigación Sanitaria, Ministerio Español de Economía y Competitividad (grants FIS PI19/00301, PI22/00258, PI22/00023 and PI23/01065); CIBER—Consorcio Centro de Investigación Biomédica en Red—(CIBERINFEC, ISCIII—CIBER de Enfermedades Infecciosas & CIBEREHD, ISCIII. CIBER de Enfermedades Hepáticas y Digestivas), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea—NextGenerationEU; S.C.-C received support from the Spanish Ministry of Education grant FPU21/04150. M.I.-L. received the support of a fellowship from ”La Caixa” Foundation (ID 100010434), whose code is “LCF/BQ/DR23/12000020”. C.C. has received a fellowship from VHIR.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Association of Liver Damage and Quasispecies Maturity in Chronic HCV Patients: The Fate of a Quasispecies

  • Garcia-Cehic, Damir
  • Gregori Font, Josep
  • Ibañez Lligoña, Marta
  • Colomer-Castell, Sergi
  • Campos, Carolina
  • QUER, JOSEP
Fibrosis; Liver damage; Quasispecies maturity, Fibrosi; Dany hepàtic; Maduresa de quasiespècies, Fibrosis; Daño hepático; Madurez de cuasiespecies, Viral diversity and disease progression in chronic infections, and particularly how quasispecies structure affects antiviral treatment, remain key unresolved issues. Previous studies show that advanced liver fibrosis in long-term viral infections is linked to higher rates of antiviral treatment failures. Additionally, treatment failure is associated with high quasispecies fitness, which indicates greater viral diversity and adaptability. As a result, resistant variants may emerge, reducing retreatment effectiveness and increasing the chances of viral relapse. Additionally, using a mutagenic agent in monotherapy can accelerate virus evolution towards a flat-like quasispecies structure. This study examines 19 chronic HCV patients who failed direct-acting antiviral (DAA) treatments, using NGS to analyze quasispecies structure in relation to fibrosis as a marker of infection duration. Results show that HCV evolves towards a flat-like quasispecies structure over time, leading also to advanced liver damage (fibrosis F3 and F4/cirrhosis). Based on our findings and previous research, we propose that the flat-like fitness quasispecies structure is the final stage of any quasispecies in chronic infections unless eradicated. The longer the infection persists, the lower the chances of achieving a cure. Interestingly, this finding may also be applicable to other chronic infection and drug resistance in cancer., This study was partially supported by Plan Estratègic de Recerca i Innovació en Salut (PERIS)—Direcció General de Recerca i Innovació en Salut (DGRIS), Catalan Health Ministry, Generalitat de Catalunya; Centro para el Desarrollo Tecnológico Industrial (CDTI) of the Spanish Ministry of Economy and Business, grant number IDI-20200297; and Project PI22/00258 funded by Instituto de Salud Carlos III (ISCIII) and cofounded by the European Union. S.C.-C has received support from the Spanish Ministry of Education, grant FPU21/04150. M.I.-L. received the support of a fellowship from the “la Caixa” Foundation (ID 100010434), whose code is LCF/BQ/DR23/12000020. C.C. received a predoctoral fellowship from VHIR.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Viral Quasispecies Inference from Single Observations—Mutagens as Accelerators of Quasispecies Evolution

  • Salicrú, Miquel
  • González Camuesco, Álvaro
  • Gregori Font, Josep
  • Ibañez Lligoña, Marta
  • Colomer-Castell, Sergi
  • Campos, Carolina
  • QUER, JOSEP
RNA-virus; Inference; Inhibitors, Virus d'ARN; Inferència; Inhibidors, Virus ARN; Inferencia; Inhibidores, RNA virus populations exist as quasispecies-complex, dynamic clouds of closely related but genetically diverse variants generated by high mutation rates during replication. Assessing quasispecies structure and diversity is crucial for understanding viral evolution, adaptation, and response to antiviral treatments. However, comparing single quasispecies observations from individual biosamples, especially at different infection or treatment time points, presents statistical challenges. Traditional inferential tests are inapplicable due to the lack of replicate observations, and resampling-based approaches such as the bootstrap and jackknife are limited by biases and non-independence, particularly for diversity indices sensitive to rare haplotypes. In this study, we address these limitations by applying the delta method to derive analytical variances for a set of quasispecies structure indicators specifically designed to assess the quasispecies maturation state. We demonstrate the utility of this approach using high-depth next-generation sequencing data from hepatitis C virus (HCV) quasispecies evolving in vitro under various conditions, including free evolution and exposure to antiviral or mutagenic treatments. Our results reveal that with highly fit HCV quasispecies, sofosbuvir inhibits quasispecies genetic diversity, while mutagenic treatments accelerate maturation, compared to untreated controls. We emphasize the interpretation of results through absolute differences, log-fold changes, and standardized effect sizes, moving beyond mere statistical significance. This framework enables robust, quantitative comparisons of quasispecies diversity from single observations, providing valuable insights into viral adaptation and treatment response. The R code and session info with required libraries and versions is provided in the supplementary material., This study was partially supported by Grant PI22/00258 funded by Instituto de Salud Carlos III (ISCIII) and Grant PMPER24/00018 both under the Ministry of Science, Innovation and Universities of Spain and cofounded by the European Union; M.S. received support from the Spanish Ministry of Education Grant PID2023-148013OB-C22 and Generalitat de Catalunya Grant 2021 SGR 01421. C.C. received a predoctoral fellowship from the Vall d’Hebron Institute of Research (VHIR). M.I.-L. was supported by a fellowship from the “La Caixa” Foundation (ID 100010434), with code “LCF/BQ/DR23/12000020”. S.C.-C. received support from the Spanish Ministry of Education grant FPU21/04150.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Deep Sequencing Reveals Dual Evolution of SARS-CoV-2: Insights Into Defective Genomes From Wuhan-Hu-1 Variants to Omicron Subvariants

  • Garcia-Cehic, Damir
  • Campos, Carolina
  • Ibañez Lligoña, Marta
  • Colomer-Castell, Sergi
  • Gregori Font, Josep
  • Piñana, María
  • González-Sánchez, Alejandra
  • Rando Segura, Ariadna
  • Esperalba, Juliana
  • Saubi, Narcis
  • Cortese, Maria Francesca
  • Tabernero, David
  • Ferrer Costa, Roser
  • Esteban Mur, Juan Ignacio
  • Pumarola Suñe, Tomàs
  • QUER, JOSEP
  • Antón Pagarolas, Andrés
  • Andrés Vergés, Cristina
Omicron; Deep‐sequencing; Dual evolution, Òmicron; Seqüenciació profunda; Evolució dual, Ómicron; Secuenciación profunda; Evolución dual, SARS-CoV-2 has evolved from early variants dominating the first (B.1.5, B.1.1) and second (B.1.177) pandemic waves, which exhibited a higher frequency of minority mutants with deletions leading to Defective Viral Genomes (DVGs) in the spike region near the S1/S2 cleavage site than the Alpha, Beta, and Delta variants. The emergence of Omicron has significantly altered the dominant variant profile, with Omicron subvariants now representing 100% of circulating viruses. To monitor the evolution and adaptation of Omicron in the human population, a deep-sequencing study was performed in RNA samples of BA.1, BA.1.1, BA.2, BA.5, BQ.1.1, XBB.1.5 and BA.2.86 Omicron subvariants. The findings reveal two occurrences of similar evolutionary patterns within SARS-CoV-2 characterized by a shift from a significant to a very low production of DVGs. This event suggests that DVGs might play a role in the virus's spread and adaptation for persistence in infected humans., This study was supported by the Centro para el Desarrollo Tecnológico Industrial (CDTI) of the Spanish Ministry of Economy and Business, grant number IDI-20200297; Grant PID2021-126447OB-I00 funded by MCIN/AEI/10.13039/501100011033 and by the ERDF A way of making Europe; Fondo de Investigación Sanitaria, Spanish Ministry of Economy and Competitiveness (grants FIS PI19/00301, PI19/00533, PI22/00258, PI22/00023, and PI23/01065); CIBER—Consorcio Centro de Investigación Biomédica en Red—(CIBERINFEC, ISCIII—CIBER of Infectious Diseases & CIBEREHD, ISCIII—CIBER of Hepatic and Digestive Diseases), Instituto de Salud Carlos III, Ministry of Science and Innovation and the European Union—NextGenerationEU. Research contributions of Wageningen Bioveterinary Research are funded from the ERRAZE (Early Response and Rapid Action Zoonotic Emergencies Program). C.C. received a predoctoral fellowship from the Vall d'Hebron Institute of Research (VHIR). M.I.-L. was supported by a fellowship from the “La Caixa” Foundation (ID 100010434), with code “LCF/BQ/DR23/12000020”. S.C-C. received support from the Spanish Ministry of Education grant FPU21/04150.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Complete Genome Sequences of Four Mycobacteriophages Involved in Directed Evolution against Undisputed Mycobacterium abscessus Clinical Strains

  • Cao Yao, Juan Carlos
  • Navas Méndez, Jesús
  • Dorta-Gorrín, Alexis
  • Garcia-Hevia, Lorena
  • Garcia-Cehic, Damir
  • QUER, JOSEP
  • Tórtola Fernández, María Teresa
Mycobacterium; Cluster; Gene, Micobacteria; Clúster; Gen, Micobactèria; Clúster; Gen, Phage therapy is still in its infancy, but it is increasingly promising as a future alternative for treating antibiotic-resistant bacteria. To investigate the effect of phages on Mycobacterium abscessus complex (MABC), we isolated 113 environmental phages, grown them to high titres, and assayed them on MABC clinical strains through the spot test. Of all the phages, only 16 showed killing activity. Their activity was so temperate to MABC that they could not generate any plaque-forming units (PFUs). The Appelmans method of directed evolution was carried out to evolve these 16 phages into more lytic ones. After only 11 of 30 rounds of evolution, every single clinical strain in our collection, including those that were unsusceptible up to this point, could be lysed by at least one phage. The evolved phages were able to form PFUs on the clinical strains tested. Still, they are temperate at best and require further training. The genomes of one random parental phage and three random evolved phages from Round 13 were sequenced, revealing a diversity of clusters and genes of a variety of evolutionary origins, mostly of unknown function. These complete annotated genomes will be key for future molecular characterisations., This research received financial support from Mutua Madrileña for the project ‘Formulación de bacteriófagos como liposomas y nanopartículas con aplicación potencial al tratamiento de infecciones de pacientes de fibrosis quística’, and is part of Project P122/00258, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union and Centro para el Desarrollo Tecnológico Industrial (CDTI) from the Spanish Ministry of Economy, Trade and Enterprise (MINECO), with grant number IDI20200297.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Quantifying In-Host Quasispecies Evolution

  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Ibañez Lligoña, Marta|||0000-0003-3428-2168
  • Quer, Josep|||0000-0003-0014-084X
What takes decades, centuries or millennia to happen with a natural ecosystem, it takes only days, weeks or months with a replicating viral quasispecies in a host, especially when under treatment. Some methods to quantify the evolution of a quasispecies are introduced and discussed, along with simple simulated examples to help in the interpretation and understanding of the results. The proposed methods treat the molecules in a quasispecies as individuals of competing species in an ecosystem, where the haplotypes are the competing species, and the ecosystem is the quasispecies in a host, and the evolution of the system is quantified by monitoring changes in haplotype frequencies. The correlation between the proposed indices is also discussed, and the R code used to generate the simulations, the data and the plots is provided. The virtues of the proposed indices are finally shown on a clinical case.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Bioinformatic Tools for NGS-Based Metagenomics to Improve the Clinical Diagnosis of Emerging, Re-Emerging and New Viruses

  • Ibañez Lligoña, Marta|||0000-0003-3428-2168
  • Colomer Castell, Sergi|||0000-0002-0307-7455
  • González Sánchez, Alejandra|||0000-0002-1809-3415
  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Campos, Carolina|||0000-0002-0132-7027
  • Garcia-Cehic, D.|||0000-0002-0009-038X
  • Andrés, Cristina|||0000-0002-3200-0895
  • Piñana, Maria|||0000-0002-4766-2613
  • Pumarola Suñé, Tomàs|||0000-0002-5171-7461
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
  • Antón Pagarolas, Andrés, 1976-|||0000-0002-1476-0815
  • Quer, Josep|||0000-0003-0014-084X
Epidemics and pandemics have occurred since the beginning of time, resulting in millions of deaths. Many such disease outbreaks are caused by viruses. Some viruses, particularly RNA viruses, are characterized by their high genetic variability, and this can affect certain phenotypic features: tropism, antigenicity, and susceptibility to antiviral drugs, vaccines, and the host immune response. The best strategy to face the emergence of new infectious genomes is prompt identification. However, currently available diagnostic tests are often limited for detecting new agents. High-throughput next-generation sequencing technologies based on metagenomics may be the solution to detect new infectious genomes and properly diagnose certain diseases. Metagenomic techniques enable the identification and characterization of disease-causing agents, but they require a large amount of genetic material and involve complex bioinformatic analyses. A wide variety of analytical tools can be used in the quality control and pre-processing of metagenomic data, filtering of untargeted sequences, assembly and quality control of reads, and taxonomic profiling of sequences to identify new viruses and ones that have been sequenced and uploaded to dedicated databases. Although there have been huge advances in the field of metagenomics, there is still a lack of consensus about which of the various approaches should be used for specific data analysis tasks. In this review, we provide some background on the study of viral infections, describe the contribution of metagenomics to this field, and place special emphasis on the bioinformatic tools (with their capabilities and limitations) available for use in metagenomic analyses of viral pathogens.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Plasma extracellular vesicles reveal early molecular differences in amyloid positive patients with early-onset mild cognitive impairment

  • Cano, Amanda|||0000-0001-9567-4283
  • Esteban de Antonio, Ester|||0000-0003-1965-6010
  • Bernuz, Mireia|||0000-0002-2052-6902
  • Puerta, Raquel|||0000-0002-1191-5893
  • García-González, Pablo|||0000-0003-0125-5403
  • De Rojas, Itziar|||0000-0002-2148-381X
  • Olivé Roig, Clàudia|||0000-0002-9438-5639
  • Pérez-Cordón, Alba|||0000-0002-6028-0791
  • Montrreal Navarro, Laura|||0000-0002-0010-645X
  • Núñez-Llaves, Raúl|||0000-0002-6702-4774
  • Sotolongo Grau, Oscar|||0000-0002-9679-0670
  • Alarcón-Martín, Emilio|||0000-0002-0985-872X
  • Valero, Sergi|||0000-0002-6599-948X
  • Alegret, Montserrat|||0000-0002-8164-9500
  • Martín, Elvira
  • Martino-Adami, Pamela V.
  • Ettcheto, Miren|||0000-0002-4301-7297
  • Camins, Antoni|||0000-0002-1229-5956
  • Vivas, Assumpta
  • Gómez Chiari, Marta|||0000-0001-6726-1721
  • Tejero, Miguel Ángel
  • Orellana del Río, Adelina|||0000-0002-0204-1944
  • Tárraga, Lluís|||0000-0002-8423-946X
  • Marquié, Marta|||0000-0002-0660-0950
  • Ramirez, Alfredo|||0000-0003-4991-763X
  • Martí, Mercè|||0000-0002-1846-0043
  • Pividori, María Isabel|||0000-0002-5266-7873
  • Boada, Mercè|||0000-0003-2617-3009
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
In the clinical course of Alzheimer's disease (AD) development, the dementia phase is commonly preceded by a prodromal AD phase, which is mainly characterized by reaching the highest levels of Aβ and p-tau-mediated neuronal injury and a mild cognitive impairment (MCI) clinical status. Because of that, most AD cases are diagnosed when neuronal damage is already established and irreversible. Therefore, a differential diagnosis of MCI causes in these prodromal stages is one of the greatest challenges for clinicians. Blood biomarkers are emerging as desirable tools for pre-screening purposes, but the current results are still being analyzed and much more data is needed to be implemented in clinical practice. Because of that, plasma extracellular vesicles (pEVs) are gaining popularity as a new source of biomarkers for the early stages of AD development. To identify an exosome proteomics signature linked to prodromal AD, we performed a cross-sectional study in a cohort of early-onset MCI (EOMCI) patients in which 184 biomarkers were measured in pEVs, cerebrospinal fluid (CSF), and plasma samples using multiplex PEA technology of Olink© proteomics. The obtained results showed that proteins measured in pEVs from EOMCI patients with established amyloidosis correlated with CSF p-tau181 levels, brain ventricle volume changes, brain hyperintensities, and MMSE scores. In addition, the correlations of pEVs proteins with different parameters distinguished between EOMCI Aβ( +) and Aβ(-) patients, whereas the CSF or plasma proteome did not. In conclusion, our findings suggest that pEVs may be able to provide information regarding the initial amyloidotic changes of AD. Circulating exosomes may acquire a pathological protein signature of AD before raw plasma, becoming potential biomarkers for identifying subjects at the earliest stages of AD development.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Extracellular vesicles, the emerging mirrors of brain physiopathology

  • Cano, Amanda|||0000-0001-9567-4283
  • Ettcheto, Miren|||0000-0002-4301-7297
  • Bernuz, Mireia|||0000-0002-2052-6902
  • Puerta, Raquel|||0000-0002-1191-5893
  • Esteban de Antonio, Ester|||0000-0003-1965-6010
  • Sánchez-López, Elena|||0000-0003-2571-108X
  • Souto, Eliana B.
  • Camins, Antoni|||0000-0002-1229-5956
  • Martí, Mercè|||0000-0002-1846-0043
  • Pividori, María Isabel|||0000-0002-5266-7873
  • Boada, Mercè|||0000-0003-2617-3009
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
Extracellular vesicles are secreted by a wide variety of cells, and their primary functions include intercellular communication, immune responses, human reproduction, and synaptic plasticity. Their molecular cargo reflects the physiological processes that their cells of origin are undergoing. Thus, many studies have suggested that extracellular vesicles could be a promising biomarker tool for many diseases, mainly due to their biological relevance and easy accessibility to a broad range of body fluids. Moreover, since their biological composition leads them to cross the blood-brain barrier bidirectionally, growing evidence points to extracellular vesicles as emerging mirrors of brain diseases processes. In this regard, this review explores the biogenesis and biological functions of extracellular vesicles, their role in different physiological and pathological processes, their potential in clinical practice, and the recent outstanding studies about the role of exosomes in major human brain diseases, such as Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or brain tumors.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

In-Host Flat-like Quasispecies, Characterization Methods and Clinical Implications

  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Colomer Castell, Sergi|||0000-0002-0307-7455
  • Ibañez Lligoña, Marta|||0000-0003-3428-2168
  • Garcia-Cehic, D.|||0000-0002-0009-038X
  • Campos, Carolina|||0000-0002-0132-7027
  • Buti, Maria|||0000-0002-0732-3078
  • Riveiro Barciela, Mar|||0000-0001-9309-2052
  • Andrés, Cristina|||0000-0002-3200-0895
  • Piñana, Maria|||0000-0002-4766-2613
  • González Sánchez, Alejandra|||0000-0002-1809-3415
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
  • Cortese, Maria Francesca|||0000-0002-4318-532X
  • Tabernero, David|||0000-0002-1146-4084
  • Rando-Segura, Ariadna|||0000-0003-4555-7286
  • Pumarola Suñé, Tomàs|||0000-0002-5171-7461
  • Esteban Mur, Juan Ignacio|||0000-0001-5085-917X
  • Antón Pagarolas, Andrés, 1976-|||0000-0002-1476-0815
  • Quer, Josep|||0000-0003-0014-084X
The repeated failure to treat patients chronically infected with hepatitis E (HEV) and C (HCV) viruses, despite the absence of resistance-associated substitutions (RAS), particularly in response to prolonged treatments with the mutagenic agents of HEV, suggests that quasispecies structure may play a crucial role beyond single point mutations. Quasispecies structured in a flat-like manner (referred to as flat-like) are considered to possess high average fitness, occupy a significant fraction of the functional genetic space of the virus, and exhibit a high capacity to evade specific or mutagenic treatments. In this paper, we studied HEV and HCV samples using high-depth next-generation sequencing (NGS), with indices scoring the different properties describing flat-like quasispecies. The significance of these indices was demonstrated by comparing the values obtained from these samples with those from acute infections caused by respiratory viruses (betacoronaviruses, enterovirus, respiratory syncytial viruses, and metapneumovirus). Our results revealed that flat-like quasispecies in HEV and HCV chronic infections without RAS are characterized by numerous low-frequency haplotypes with no dominant one. Surprisingly, these low-frequency haplotypes (at the nucleotide level) exhibited a high level of synonymity, resulting in much lower diversity at the phenotypic level. Currently, clinical approaches for managing flat-like quasispecies are lacking. Here, we propose methods to identifying flat-like quasispecies, which represents an essential initial step towards exploring alternative treatment protocols for viruses resistant to conventional therapies.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

In-Host Flat-like Quasispecies: Characterization Methods and Clinical Implications

  • Gregori Font, Josep
  • Colomer-Castell, Sergi
  • Ibañez Lligoña, Marta
  • Garcia-Cehic, Damir
  • Campos, Carolina
  • Riveiro-Barciela, Mar
  • Piñana, María
  • González-Sánchez, Alejandra
  • RODRIGUEZ-FRIAS, FRANCISCO
  • Cortese, Maria Francesca
  • Tabernero, David
  • Rando Segura, Ariadna
  • Pumarola Suñe, Tomàs
  • Esteban Mur, Juan Ignacio
  • QUER, JOSEP
  • Buti Ferret, Maria
  • Antón Pagarolas, Andrés
  • Andrés Vergés, Cristina
Cuasiespecies; Mutágenos; Mutaciones, Quasispecies; Mutagens; Mutations, Quasiespècie; Mutàgens; Mutacions, The repeated failure to treat patients chronically infected with hepatitis E (HEV) and C (HCV) viruses, despite the absence of resistance-associated substitutions (RAS), particularly in response to prolonged treatments with the mutagenic agents of HEV, suggests that quasispecies structure may play a crucial role beyond single point mutations. Quasispecies structured in a flat-like manner (referred to as flat-like) are considered to possess high average fitness, occupy a significant fraction of the functional genetic space of the virus, and exhibit a high capacity to evade specific or mutagenic treatments. In this paper, we studied HEV and HCV samples using high-depth next-generation sequencing (NGS), with indices scoring the different properties describing flat-like quasispecies. The significance of these indices was demonstrated by comparing the values obtained from these samples with those from acute infections caused by respiratory viruses (betacoronaviruses, enterovirus, respiratory syncytial viruses, and metapneumovirus). Our results revealed that flat-like quasispecies in HEV and HCV chronic infections without RAS are characterized by numerous low-frequency haplotypes with no dominant one. Surprisingly, these low-frequency haplotypes (at the nucleotide level) exhibited a high level of synonymity, resulting in much lower diversity at the phenotypic level. Currently, clinical approaches for managing flat-like quasispecies are lacking. Here, we propose methods to identifying flat-like quasispecies, which represents an essential initial step towards exploring alternative treatment protocols for viruses resistant to conventional therapies., This study was partially supported by Centro para el Desarrollo Tecnológico Industrial (CDTI) from the Spanish Ministry of Economy and Business, grant number IDI-20200297; Grant PID2021-126447OB-I00 funded by MCIN/AEI/10.13039/501100011033 and by ERDF A way of making Europe; Fondo de Investigación Sanitaria, Ministerio Español de Economía y Competitividad (grants FIS PI19/00301, PI22/00258, PI22/00023 and PI23/01065); CIBER—Consorcio Centro de Investigación Biomédica en Red—(CIBERINFEC, ISCIII—CIBER de Enfermedades Infecciosas & CIBEREHD, ISCIII. CIBER de Enfermedades Hepáticas y Digestivas), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea—NextGenerationEU; S.C.-C received support from the Spanish Ministry of Education grant FPU21/04150. M.I.-L. received the support of a fellowship from ”La Caixa” Foundation (ID 100010434), whose code is “LCF/BQ/DR23/12000020”. C.C. has received a fellowship from VHIR.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Association of Liver Damage and Quasispecies Maturity in Chronic HCV Patients: The Fate of a Quasispecies

  • Garcia-Cehic, Damir
  • Gregori Font, Josep
  • Ibañez Lligoña, Marta
  • Colomer-Castell, Sergi
  • Campos, Carolina
  • QUER, JOSEP
Fibrosis; Liver damage; Quasispecies maturity, Fibrosi; Dany hepàtic; Maduresa de quasiespècies, Fibrosis; Daño hepático; Madurez de cuasiespecies, Viral diversity and disease progression in chronic infections, and particularly how quasispecies structure affects antiviral treatment, remain key unresolved issues. Previous studies show that advanced liver fibrosis in long-term viral infections is linked to higher rates of antiviral treatment failures. Additionally, treatment failure is associated with high quasispecies fitness, which indicates greater viral diversity and adaptability. As a result, resistant variants may emerge, reducing retreatment effectiveness and increasing the chances of viral relapse. Additionally, using a mutagenic agent in monotherapy can accelerate virus evolution towards a flat-like quasispecies structure. This study examines 19 chronic HCV patients who failed direct-acting antiviral (DAA) treatments, using NGS to analyze quasispecies structure in relation to fibrosis as a marker of infection duration. Results show that HCV evolves towards a flat-like quasispecies structure over time, leading also to advanced liver damage (fibrosis F3 and F4/cirrhosis). Based on our findings and previous research, we propose that the flat-like fitness quasispecies structure is the final stage of any quasispecies in chronic infections unless eradicated. The longer the infection persists, the lower the chances of achieving a cure. Interestingly, this finding may also be applicable to other chronic infection and drug resistance in cancer., This study was partially supported by Plan Estratègic de Recerca i Innovació en Salut (PERIS)—Direcció General de Recerca i Innovació en Salut (DGRIS), Catalan Health Ministry, Generalitat de Catalunya; Centro para el Desarrollo Tecnológico Industrial (CDTI) of the Spanish Ministry of Economy and Business, grant number IDI-20200297; and Project PI22/00258 funded by Instituto de Salud Carlos III (ISCIII) and cofounded by the European Union. S.C.-C has received support from the Spanish Ministry of Education, grant FPU21/04150. M.I.-L. received the support of a fellowship from the “la Caixa” Foundation (ID 100010434), whose code is LCF/BQ/DR23/12000020. C.C. received a predoctoral fellowship from VHIR.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Virus Quasispecies Rarefaction: Subsampling with or without Replacement?

  • Gregori Font, Josep
  • Ibañez Lligoña, Marta
  • Colomer-Castell, Sergi
  • Campos, Carolina
  • QUER, JOSEP
Haplotypes; Quasispecies; Rarefaction, Haplotips; Quasiespècie; Rarefacció, Haplotipos; Cuasiespecie; Rarefacción, In quasispecies diversity studies, the comparison of two samples of varying sizes is a common necessity. However, the sensitivity of certain diversity indices to sample size variations poses a challenge. To address this issue, rarefaction emerges as a crucial tool, serving to normalize and create fairly comparable samples. This study emphasizes the imperative nature of sample size normalization in quasispecies diversity studies using next-generation sequencing (NGS) data. We present a thorough examination of resampling schemes using various simple hypothetical cases of quasispecies showing different quasispecies structures in the sense of haplotype genomic composition, offering a comprehensive understanding of their implications in general cases. Despite the big numbers implied in this sort of study, often involving coverages exceeding 100,000 reads per sample and amplicon, the rarefaction process for normalization should be performed with repeated resampling without replacement, especially when rare haplotypes constitute a significant fraction of interest. However, it is noteworthy that different diversity indices exhibit distinct sensitivities to sample size. Consequently, some diversity indicators may be compared directly without normalization, or instead may be resampled safely with replacement., This study was partially supported by Plan Estratègic de Recerca i Innovació en Salut (PERIS)—Direcció General de Recerca i Innovació en Salut (DGRIS), Catalan Health Ministry, Generalitat de Catalunya; Centro para el Desarrollo Tecnológico Industrial (CDTI) from the Spanish Ministry of Economy and Business, grant number IDI-20200297; and Project PI22/00258 funded by Instituto de Salud Carlos III (ISCIII) and cofounded by the European Union. S.C.-C has received support from the Spanish Ministry of Education, grant FPU21/04150. M.I.-L. received the support of a fellowship from the “la Caixa” Foundation (ID 100010434), whose code is LCF/BQ/DR23/12000020, C.C. received a predoctoral fellowship from VHIR.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Viral Quasispecies Inference from Single Observations—Mutagens as Accelerators of Quasispecies Evolution

  • Salicrú, Miquel
  • González Camuesco, Álvaro
  • Gregori Font, Josep
  • Ibañez Lligoña, Marta
  • Colomer-Castell, Sergi
  • Campos, Carolina
  • QUER, JOSEP
RNA-virus; Inference; Inhibitors, Virus d'ARN; Inferència; Inhibidors, Virus ARN; Inferencia; Inhibidores, RNA virus populations exist as quasispecies-complex, dynamic clouds of closely related but genetically diverse variants generated by high mutation rates during replication. Assessing quasispecies structure and diversity is crucial for understanding viral evolution, adaptation, and response to antiviral treatments. However, comparing single quasispecies observations from individual biosamples, especially at different infection or treatment time points, presents statistical challenges. Traditional inferential tests are inapplicable due to the lack of replicate observations, and resampling-based approaches such as the bootstrap and jackknife are limited by biases and non-independence, particularly for diversity indices sensitive to rare haplotypes. In this study, we address these limitations by applying the delta method to derive analytical variances for a set of quasispecies structure indicators specifically designed to assess the quasispecies maturation state. We demonstrate the utility of this approach using high-depth next-generation sequencing data from hepatitis C virus (HCV) quasispecies evolving in vitro under various conditions, including free evolution and exposure to antiviral or mutagenic treatments. Our results reveal that with highly fit HCV quasispecies, sofosbuvir inhibits quasispecies genetic diversity, while mutagenic treatments accelerate maturation, compared to untreated controls. We emphasize the interpretation of results through absolute differences, log-fold changes, and standardized effect sizes, moving beyond mere statistical significance. This framework enables robust, quantitative comparisons of quasispecies diversity from single observations, providing valuable insights into viral adaptation and treatment response. The R code and session info with required libraries and versions is provided in the supplementary material., This study was partially supported by Grant PI22/00258 funded by Instituto de Salud Carlos III (ISCIII) and Grant PMPER24/00018 both under the Ministry of Science, Innovation and Universities of Spain and cofounded by the European Union; M.S. received support from the Spanish Ministry of Education Grant PID2023-148013OB-C22 and Generalitat de Catalunya Grant 2021 SGR 01421. C.C. received a predoctoral fellowship from the Vall d’Hebron Institute of Research (VHIR). M.I.-L. was supported by a fellowship from the “La Caixa” Foundation (ID 100010434), with code “LCF/BQ/DR23/12000020”. S.C.-C. received support from the Spanish Ministry of Education grant FPU21/04150.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Complete Genome Sequences of Four Mycobacteriophages Involved in Directed Evolution against Undisputed Mycobacterium abscessus Clinical Strains

  • Cao Yao, Juan Carlos
  • Navas Méndez, Jesús
  • Dorta-Gorrín, Alexis
  • Garcia-Hevia, Lorena
  • Garcia-Cehic, Damir
  • QUER, JOSEP
  • Tórtola Fernández, María Teresa
Mycobacterium; Cluster; Gene, Micobacteria; Clúster; Gen, Micobactèria; Clúster; Gen, Phage therapy is still in its infancy, but it is increasingly promising as a future alternative for treating antibiotic-resistant bacteria. To investigate the effect of phages on Mycobacterium abscessus complex (MABC), we isolated 113 environmental phages, grown them to high titres, and assayed them on MABC clinical strains through the spot test. Of all the phages, only 16 showed killing activity. Their activity was so temperate to MABC that they could not generate any plaque-forming units (PFUs). The Appelmans method of directed evolution was carried out to evolve these 16 phages into more lytic ones. After only 11 of 30 rounds of evolution, every single clinical strain in our collection, including those that were unsusceptible up to this point, could be lysed by at least one phage. The evolved phages were able to form PFUs on the clinical strains tested. Still, they are temperate at best and require further training. The genomes of one random parental phage and three random evolved phages from Round 13 were sequenced, revealing a diversity of clusters and genes of a variety of evolutionary origins, mostly of unknown function. These complete annotated genomes will be key for future molecular characterisations., This research received financial support from Mutua Madrileña for the project ‘Formulación de bacteriófagos como liposomas y nanopartículas con aplicación potencial al tratamiento de infecciones de pacientes de fibrosis quística’, and is part of Project P122/00258, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union and Centro para el Desarrollo Tecnológico Industrial (CDTI) from the Spanish Ministry of Economy, Trade and Enterprise (MINECO), with grant number IDI20200297.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Deep Sequencing Reveals Dual Evolution of SARS-CoV-2: Insights Into Defective Genomes From Wuhan-Hu-1 Variants to Omicron Subvariants

  • Garcia-Cehic, Damir
  • Campos, Carolina
  • Ibañez Lligoña, Marta
  • Colomer-Castell, Sergi
  • Gregori Font, Josep
  • Piñana, María
  • González-Sánchez, Alejandra
  • Rando Segura, Ariadna
  • Esperalba, Juliana
  • Saubi, Narcis
  • Cortese, Maria Francesca
  • Tabernero, David
  • Ferrer Costa, Roser
  • Esteban Mur, Juan Ignacio
  • Pumarola Suñe, Tomàs
  • QUER, JOSEP
  • Antón Pagarolas, Andrés
  • Andrés Vergés, Cristina
Omicron; Deep‐sequencing; Dual evolution, Òmicron; Seqüenciació profunda; Evolució dual, Ómicron; Secuenciación profunda; Evolución dual, SARS-CoV-2 has evolved from early variants dominating the first (B.1.5, B.1.1) and second (B.1.177) pandemic waves, which exhibited a higher frequency of minority mutants with deletions leading to Defective Viral Genomes (DVGs) in the spike region near the S1/S2 cleavage site than the Alpha, Beta, and Delta variants. The emergence of Omicron has significantly altered the dominant variant profile, with Omicron subvariants now representing 100% of circulating viruses. To monitor the evolution and adaptation of Omicron in the human population, a deep-sequencing study was performed in RNA samples of BA.1, BA.1.1, BA.2, BA.5, BQ.1.1, XBB.1.5 and BA.2.86 Omicron subvariants. The findings reveal two occurrences of similar evolutionary patterns within SARS-CoV-2 characterized by a shift from a significant to a very low production of DVGs. This event suggests that DVGs might play a role in the virus's spread and adaptation for persistence in infected humans., This study was supported by the Centro para el Desarrollo Tecnológico Industrial (CDTI) of the Spanish Ministry of Economy and Business, grant number IDI-20200297; Grant PID2021-126447OB-I00 funded by MCIN/AEI/10.13039/501100011033 and by the ERDF A way of making Europe; Fondo de Investigación Sanitaria, Spanish Ministry of Economy and Competitiveness (grants FIS PI19/00301, PI19/00533, PI22/00258, PI22/00023, and PI23/01065); CIBER—Consorcio Centro de Investigación Biomédica en Red—(CIBERINFEC, ISCIII—CIBER of Infectious Diseases & CIBEREHD, ISCIII—CIBER of Hepatic and Digestive Diseases), Instituto de Salud Carlos III, Ministry of Science and Innovation and the European Union—NextGenerationEU. Research contributions of Wageningen Bioveterinary Research are funded from the ERRAZE (Early Response and Rapid Action Zoonotic Emergencies Program). C.C. received a predoctoral fellowship from the Vall d'Hebron Institute of Research (VHIR). M.I.-L. was supported by a fellowship from the “La Caixa” Foundation (ID 100010434), with code “LCF/BQ/DR23/12000020”. S.C-C. received support from the Spanish Ministry of Education grant FPU21/04150.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Genotyping Hepatitis B virus by Next-Generation Sequencing: Detection of Mixed Infections and Analysis of Sequence Conservation

  • Dopico, Eva
  • Vila Salvador, Marta
  • Pacin Ruiz, Beatriz
  • Pérez Garreta, Javier
  • Buti Ferret, Maria
  • Tabernero, David
  • Gregori Font, Josep
  • Rando Segura, Ariadna
  • QUER, JOSEP
  • González-Sánchez, Alejandra
  • Pumarola Suñe, Tomàs
  • Riveiro-Barciela, Mar
  • Ferrer Costa, Roser
  • RODRIGUEZ-FRIAS, FRANCISCO
  • Cortese, Maria Francesca
  • Antón Pagarolas, Andrés
RNA interference; Hepatitis B X gene; Next-generation sequencing, Interferència d'ARN; Gen de l'hepatitis BX; Seqüenciació de nova generació, Interferencia de ARN; Gen de la hepatitis BX; Secuenciación de nueva generación, Our aim was to develop an accurate, highly sensitive method for HBV genotype determination and detection of genotype mixtures. We examined the preS and 5' end of the HBV X gene (5X) regions of the HBV genome using next-generation sequencing (NGS). The 1852 haplotypes obtained were subjected to genotyping via the Distance-Based discrimination method (DB Rule) using two sets of 95 reference sequences of genotypes A-H. In clinical samples from 125 patients, the main genotypes were A, D, F and H in Caucasian, B and C in Asian and A and E in Sub-Saharan patients. Genotype mixtures were identified in 28 (22.40%) cases, and potential intergenotypic recombination was observed in 29 (23.20%) cases. Furthermore, we evaluated sequence conservation among haplotypes classified into genotypes A, C, D, and E by computing the information content. The preS haplotypes exhibited limited shared conserved regions, whereas the 5X haplotypes revealed two groups of conserved regions across the genotypes assessed. In conclusion, we developed an NGS-based HBV genotyping method utilizing the DB Rule for genotype classification. We identified two regions conserved across different genotypes at 5X, offering promising targets for RNA interference-based antiviral therapies., This research was funded by the grant PID2021-126447OB-I00 funded by MCIN/AEI/10.13039/501100011033 and by ERDF A way of making Europe; Centro para el Desarrollo Tecnológico Industrial (CDTI) from the Spanish Ministry of Economy and Business, grant number IDI-20200297; Projects PI19/00301 and PI22/00258 funded by Instituto de Salud Carlos III (ISCIII) and cofounded by the European Union.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Unveiling pathogens and contaminants: refining metagenomics for clinical diagnostics

  • Garcia-Larroy, Jorgina
  • Antón Pagarolas, Andrés
  • Ibañez Lligoña, Marta
  • Colomer-Castell, Sergi
  • Campos, Carolina
  • González Camuesco, Álvaro
  • Llaurado, Arnau
  • Sánchez-Tejerina, Daniel
  • Rando Segura, Ariadna
  • Andrés Vergés, Cristina
  • Esperalba, Juliana
  • Nadal-Barón, Patricia
  • Ferrer Costa, Roser
  • Cortese, Maria Francesca
  • Tabernero, David
  • Gregori Font, Josep
  • Riveiro-Barciela, Mar
  • Ruiz Cobo, Juan Carlos
  • del Barco Martínez, Ester
  • Buti Ferret, Maria
  • Goya, Maria
  • Juntas Morales, Raúl
  • QUER, JOSEP
Coinfection; Ddiagnostics; Metagenomics, Coinfección; Diagnóstico; Metagenómica, Coinfecció; Diagnòstic; Metagenòmica, Introduction: Shotgun metagenomic sequencing (mNGS), an untargeted approach that sequences all nucleic acids in a sample, has emerged as a powerful tool for pathogen detection and genome characterization. However, its implementation in clinical diagnostics remains limited due to technical challenges such as contamination and reduces sensitivity, especially in low-biomass samples.Methods: We applied mNGS to 144 clinical samples representing chronic infections, acute infections, and respiratory co-infections. To address contamination, we established a framework integrating negative controls, lab-specific contaminant watchlists, and computational filtering. Viral detection performance and genome recovery were assessed across sample types and viral loads.Results: Viral load was shown to be the primary determinant of sensitivity, with reliable recovery achieved only at higher titers. Our framework substantially improved contamination management, reducing false-positive signals and enhancing viral genome recovery. mNGS enabled the detection of clinically relevant co-infections and refined viral classification beyond targeted diagnostics, while also revealing the substantial risk of spurious detections in the absence of contamination-aware workflows.Discussion: These findings define practical sensitivity thresholds for clinical mNGS and underscore the need for contamination-aware workflows, particularly for low-biomass samples, while providing an open-source contaminants watchlist that enhances reliability and utility of clinical metagenomics., The author(s) declared that financial support was received for this work and/or its publication. This study was partially supported by Grants PI22/00258, PI22/00023, and PI23/01065 funded by Instituto de Salud Carlos III (ISCIII), Grant PMPER24/00018 and PID2021-126447OB-I00 under the Ministry of Science, Innovation and Universities of Spain and cofounded by the European Union; and Consorcio Centro de Investigación Biomédica en Red CIBERINFEC and CIBEREHD. MI-L was supported by a fellowship from the “La Caixa” Foundation (ID 100010434) with code “LCF/BQ/DR23/12000020.” SC-C received support from the Spanish Ministry of Education grant FPU21/04150. CC received a predoctoral fellowship from Vall d’Hebron Institute of Research (VHIR).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

In-Host HEV Quasispecies Evolution Shows the Limits of Mutagenic Antiviral Treatments

  • Vico-Romero, Judit
  • Campos, Carolina
  • Cortese, Maria Francesca
  • Colomer-Castell, Sergi
  • Gregori Font, Josep
  • Garcia-Cehic, Damir
  • Riveiro-Barciela, Mar
  • Rando Segura, Ariadna
  • Ibañez Lligoña, Marta
  • ADOMBI, Caroline Mélanie
  • Tabernero, David
  • Esteban Mur, Juan Ignacio
  • RODRIGUEZ-FRIAS, FRANCISCO
  • QUER, JOSEP
  • Buti Ferret, Maria
Deep sequencing; Mutagens; Quasispecies, Seqüenciació profunda; Mutàgens; Quasiespècie, Secuenciación profunda; Mutágenos; Cuasiespecie, Here, we report the in-host hepatitis E virus (HEV) quasispecies evolution in a chronically infected patient who was treated with three different regimens of ribavirin (RBV) for nearly 6 years. Sequential plasma samples were collected at different time points and subjected to RNA extraction and deep sequencing using the MiSeq Illumina platforms. Specifically, we RT-PCR amplified a single amplicon from the core region located in the open-reading frame 2 (ORF2). At the nucleotide level (genotype), our analysis showed an increase in the number of rare haplotypes and a drastic reduction in the frequency of the master (most represented) sequence during the period when the virus was found to be insensitive to RBV treatment. Contrarily, at the amino acid level (phenotype), our study revealed conservation of the amino acids, which is represented by a high prevalence of the master sequence. Our findings suggest that using mutagenic antivirals concomitant with high viral loads can lead to the selection and proliferation of a rich set of synonymous haplotypes that express the same phenotype. This can also lead to the selection and proliferation of conservative substitutions that express fitness-enhanced phenotypes. These results have important clinical implications, as they suggest that using mutagenic agents as a monotherapy treatment regimen in the absence of sufficiently effective viral inhibitors can result in diversification and proliferation of a highly diverse quasispecies resistant to further treatment. Therefore, such approaches should be avoided whenever possible., This study was partially supported by Plan Estratègic de Recerca i Innovació en Salut (PERIS)—Direcció General de Recerca i Innovació en Salut (DGRIS), Catalan Health Ministry, Generalitat de Catalunya; Centro para el Desarrollo Tecnológico Industrial (CDTI) from the Spanish Ministry of Economy and Business, grant number IDI-20200297, Grant PID2021-126447OB-I00 funded by MCIN/AEI/10.13039/501100011033 and by ERDF A way of making Europe; Projects PI19/00301 and PI22/00258 funded by Instituto de Salud Carlos III (ISCIII) and cofounded by the European Union; and Gilead’s biomedical research project GLD21/00006. S.C.-C has received support from Spanish Ministry of Education, grant FPU21/04150. M.I.-L. received the support of a fellowship from the “la Caixa” Foundation (ID 100010434), whose code is “LCF/BQ/DR23/12000020”.